Abstract:
In a phase II study testing the PD-1 inhibitor dostarlimab in locally advanced mismatch repair-deficient rectal cancer, 100% of evaluable patients experienced a clinical complete response without needing other therapies. Standard treatment for the disease, which includes chemotherapy, radiation therapy, and surgery, can lead to bowel, urinary, and sexual dysfunction, infertility, and permanent ostomy, but the study's findings suggest that neoadjuvant checkpoint blockade could spare patients these life-altering adverse events.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF


